Literature DB >> 27122702

Effects of Dexmedetomidine on L-Type Calcium Current in Rat Ventricular Myocytes.

Jing Zhao1, Chen-Liang Zhou1, Zhong-Yuan Xia1, Long Wang1.   

Abstract

BACKGROUND: Dexmedetomidine is a highly selective α2-adrenoreceptor agonist with sedative, analgesic and sympatholytic properties. Its cardiac protective effect cannot be ignored, notwithstanding its associated adverse drug reactions. This study aimed to investigate the effects of dexmedetomidine on L-type calcium current (ICa-L) in adult rat ventricular myocytes, and to clarify the electrophysiological mechanism of its effect on cardiomyocytes.
METHODS: Single rat ventricular myocytes were obtained by enzymatic dissociation method. Myocytes were perfused with external solutions containing various concentrations of dexmedetomidine at a flow rate of 2-3 ml/min for 5 min. Whole-cell current recordings were performed using the conventional whole-cell patch-clamp technique. Besides, the effects of 1 μM yohimbine, an alpha-2 adrenergic antagonist, were given alone or in combination with 10 ng/ml dexmedetomidine.
RESULTS: Dexmedetomidine inhibited the amplitude of ICa-L in a concentration-dependent manner. The current voltage curve was shifted upwards. The steady activated curves were shifted to the right and the V1/2 activation of the ICa-L were increased by dexmedetomidine at the high concentration (10 and 200 ng/ml). Dexmedetomidine did not affect the ICa-L steady-state inactivation curve, but shifted down the recovery curve. Yohimbine did not have influence on ICa-L. However, inhibition of ICa-L by dexmedetomidine at the concentration of 10 ng/ml was partially reversed by yohimbine.
CONCLUSIONS: Dexmedetomidine can attenuate ICa-L in adult rat ventricular myocytes, which may contribute to its negative effects on myocardia contractility and cardiac electrophysiology. Its inhibitory effect on ICa-L is partially associated with alpha-2 adrenergic receptors. KEY WORDS: Cardiology; Dexmedetomidine; L-type calcium current; Ventricular myocytes; Whole-cell patch clamp.

Entities:  

Year:  2013        PMID: 27122702      PMCID: PMC4804780     

Source DB:  PubMed          Journal:  Acta Cardiol Sin        ISSN: 1011-6842            Impact factor:   2.672


  15 in total

1.  Dexmedetomidine sedation (and cardiac perforation, pericardial tamponade, cardiac arrest, and cardiopulmonary resuscitation) leading to refractory cardiogenic shock.

Authors:  Michael P Hutchens; Per Thorborg
Journal:  Anesth Analg       Date:  2009-01       Impact factor: 5.108

Review 2.  Voltage-dependent calcium channels.

Authors:  L Lacinová
Journal:  Gen Physiol Biophys       Date:  2005-06       Impact factor: 1.512

3.  The effects of increasing plasma concentrations of dexmedetomidine in humans.

Authors:  T J Ebert; J E Hall; J A Barney; T D Uhrich; M D Colinco
Journal:  Anesthesiology       Date:  2000-08       Impact factor: 7.892

Review 4.  Dexmedetomidine: a review of clinical applications.

Authors:  Dominic S Carollo; Bobby D Nossaman; Usha Ramadhyani
Journal:  Curr Opin Anaesthesiol       Date:  2008-08       Impact factor: 2.706

5.  The effects of dexmedetomidine on cardiac electrophysiology in children.

Authors:  Gregory B Hammer; David R Drover; Hong Cao; Ethan Jackson; Glyn D Williams; Chandra Ramamoorthy; George F Van Hare; Alisa Niksch; Anne M Dubin
Journal:  Anesth Analg       Date:  2008-01       Impact factor: 5.108

6.  Dexmedetomidine sedation leading to refractory cardiogenic shock.

Authors:  Tina C Sichrovsky; Suneet Mittal; Jonathan S Steinberg
Journal:  Anesth Analg       Date:  2008-06       Impact factor: 5.108

Review 7.  Alpha-2 adrenergic agonists for the prevention of cardiac complications among patients undergoing surgery.

Authors:  Duminda N Wijeysundera; Jennifer S Bender; W Scott Beattie
Journal:  Cochrane Database Syst Rev       Date:  2009-10-07

8.  Dexmedetomidine: a novel drug for the treatment of atrial and junctional tachyarrhythmias during the perioperative period for congenital cardiac surgery: a preliminary study.

Authors:  Constantinos Chrysostomou; Lee Beerman; Dana Shiderly; Donald Berry; Victor O Morell; Ricardo Munoz
Journal:  Anesth Analg       Date:  2008-11       Impact factor: 5.108

9.  Dexmedetomidine, an alpha2-adrenergic agonist, inhibits neuronal delayed-rectifier potassium current and sodium current.

Authors:  B-S Chen; H Peng; S-N Wu
Journal:  Br J Anaesth       Date:  2009-06-20       Impact factor: 9.166

Review 10.  Dexmedetomidine and cardiac protection for non-cardiac surgery: a meta-analysis of randomised controlled trials.

Authors:  B M Biccard; S Goga; J de Beurs
Journal:  Anaesthesia       Date:  2008-01       Impact factor: 6.955

View more
  8 in total

1.  [Changes of myocardial calcium currents in rats with myocardial injury induced by running exercise during acute hypoxia].

Authors:  Q Dan; J Bai; Z Cai; K Lin; Y Li
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2022-09-20

2.  Electrophysiological Effects of Dexmedetomidine on Sinoatrial Nodes of Rabbits.

Authors:  Xia Pan; Zhen Zhang; Ya-Yi Huang; Jing Zhao; Long Wang
Journal:  Acta Cardiol Sin       Date:  2015-11       Impact factor: 2.672

3.  Dexmedetomidine protects H9c2 cardiomyocytes against oxygen-glucose deprivation/reoxygenation-induced intracellular calcium overload and apoptosis through regulating FKBP12.6/RyR2 signaling.

Authors:  Mei Yuan; Xiao-Wen Meng; Jiao Ma; Hong Liu; Shao-Yong Song; Qing-Cai Chen; Hua-Yue Liu; Juan Zhang; Nan Song; Fu-Hai Ji; Ke Peng
Journal:  Drug Des Devel Ther       Date:  2019-09-02       Impact factor: 4.162

4.  Dexmedetomidine exhibits antiarrhythmic effects on human-induced pluripotent stem cell-derived cardiomyocytes through a Na/Ca channel-mediated mechanism.

Authors:  Li Yang; Yiqi Gong; Yao Tan; Lei Wu; Nevin Witman; Jijian Zheng; Jun Zhang; Wei Fu; Wei Wang
Journal:  Ann Transl Med       Date:  2021-03

5.  Safe electrophysiologic profile of dexmedetomidine in different experimental arrhythmia models.

Authors:  Christian Ellermann; Jonas Brandt; Julian Wolfes; Kevin Willy; Felix K Wegner; Patrick Leitz; Philipp S Lange; Florian Reinke; Lars Eckardt; Gerrit Frommeyer
Journal:  Sci Rep       Date:  2021-12-14       Impact factor: 4.379

6.  Dexmedetomidine Attenuates LPS-Stimulated Alveolar Type II Cells' Injury through Upregulation of miR-140-3p and Partial Suppression of PD-L1 Involving Inactivating JNK-Bnip3 Pathway.

Authors:  Xianfeng Chen; Juntao Hu; Jie Lai; Zhiyong Zhang; Zhanhong Tang
Journal:  Can Respir J       Date:  2022-07-31       Impact factor: 2.130

7.  Effects of dexmedetomidine on cardiac electrophysiology in patients undergoing general anesthesia during perioperative period: a randomized controlled trial.

Authors:  Chao Tan; Shiting Yan; Jie Shen; Hao Wu; Leyang Yu; Ying Wang; Shunping Tian; Wei Zhou; Yong Wu; Zhuan Zhang
Journal:  BMC Anesthesiol       Date:  2022-08-25       Impact factor: 2.376

8.  Dexmedetomidine Exerted Anti-arrhythmic Effects in Rat With Ischemic Cardiomyopathy via Upregulation of Connexin 43 and Reduction of Fibrosis and Inflammation.

Authors:  Shu-Jie Wu; Zhong-Hao Lin; Yuan-Zheng Lin; Zhi-Heng Rao; Jia-Feng Lin; Lian-Pin Wu; Lei Li
Journal:  Front Physiol       Date:  2020-02-07       Impact factor: 4.566

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.